Brooklyn ImmunoTherapeutics Inc (BTX)

[crudeoil24]

BTX > "company said it has established a research and development center in Cambridge, Mass., to pursue its mRNA-based gene editing and cellular therapies.

The company said it has co-located with Factor Bioscience Limited and Novellus Therapeutics Limited, from which Brooklyn has acquired an exclusive worldwide license to develop and commercialize certain cell-based therapies to treat cancer and rare blood disorders, including sickle cell disease, based on the patented technology and know-how of Factor and Novellus.

"We believe co-locating with Factor and Novellus will promote our capability to leverage our collaboration and further our objectives in developing a diversified portfolio of new, advanced therapeutics," said Howard J. Federoff, Brooklyn's chief executive and president.

Brooklyn's recently licensed platform from Factor and Novellus includes three novel technologies that the company expects to pursue at its new R&D location.

The first is a highly efficient mRNA cell reprogramming method. The second is a mRNA-based gene editing technology which can be applied to both allogeneic and autologous cells and which eliminates potential for off-target effects. The third is a proprietary tunable nanolipid delivery system that provides efficient non-viral vector-based delivery of mRNA ex vivo and in vivo to skin, brain, eye and lung tissue."


Write to Chris Wack at [e-mail]